查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1775384

全球眼科藥品市場：2025-2030 年預測

Global Ophthalmic Drugs Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

眼科藥物市場預計將從 2025 年的 334.95 億美元成長到 2030 年的 470.31 億美元，複合年成長率為 7.02%。

眼科藥物市場研究為尋求有關市場動態、技術進步、競爭策略等可行見解的行業專業人士提供了不斷發展的眼科藥物行業的全面分析。該研究檢視了適應症、產品類型、劑型、藥物類別、給藥方式、分銷管道和地區等關鍵細分市場，以提供有關成長機會和挑戰的詳細見解。

調查概述

我們的眼科藥物市場研究旨在提供對市場格局的詳細了解。研究涵蓋市場促進因素、限制因素、機會以及影響市場的技術趨勢等關鍵面向。此外，研究還包含一項強而有力的競爭分析，重點主要企業的策略發展，為相關人員提供駕馭這個充滿活力的市場所需的洞見。分析涵蓋北美、南美、歐洲、中東和非洲以及亞太等地區，確保了全球觀點。

競爭格局與分析

眼科用藥市場研究深入分析了主要企業及其策略性舉措，並專注於競爭格局。主要企業之間的關鍵發展突顯了市場的動態。

  • 諾華公司：諾華正透過開發視網膜疾病治療藥物，尤其是其抗VEGF療法Beovu（brolucizumab）來鞏固其市場地位。該公司專注於擴大臨床試驗，以解決濕性老齡化黃斑部病變（AMD）領域尚未滿足的需求，並確立了其在該領域的領先地位。
  • 愛爾康公司（Ivantis）：愛爾康憑藉微創青光眼手術 (MIGS) 器械 Hydrus Microstent，在青光眼治療領域取得了重大進展。這項進展體現了愛爾康致力於整合藥物-器械聯合治療，並滿足對結膜下給藥等創新給藥方式日益成長的需求。收購 Ivantis 也增強了愛爾康的產品組合，使其在青光眼適應症領域佔據競爭優勢。

這些發展凸顯了領先公司如何利用技術創新和策略聯盟來獲得市場佔有率並滿足眼科藥品市場不斷變化的患者需求。

本報告的主要優點

  • 深刻分析：獲得涵蓋主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場。
  • 競爭格局：了解主要企業採用的策略策略，並了解正確策略的市場滲透潛力。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力進行策略決策，在動態環境中開闢新的業務流和收益。
  • 適合廣泛的使用者：對於新興企業、研究機構、顧問、中小企業和大型企業來說都是有益且具有成本效益的。

它有什麼用途？

產業與市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

調查範圍

  • 2022 年至 2024 年的實際數據和 2025 年至 2030 年的預測數據
  • 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 收益成長和預測細分市場和區域分析（包括國家）
  • 公司概況（尤其是財務狀況和關鍵發展）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 經營狀況

  • 市場促進因素
  • 市場限制
  • 市場機會
  • 波特五力分析
  • 產業價值鏈分析
  • 政策法規
  • 策略建議

第4章 技術展望

5. 全球眼科藥物市場（按適應症）

  • 介紹
  • 眼睛乾澀
  • 青光眼
  • 感染疾病/發炎/過敏
  • 視網膜問題
  • 其他

6. 全球眼科藥品市場（依產品類型）

  • 介紹
  • 非處方藥
  • 處方藥

7. 全球眼科藥物市場（按劑型）

  • 介紹
  • 液體
  • 半固體
  • 固體的

8. 全球眼科藥物市場（依藥物類別）

  • 介紹
  • 消炎（藥）
  • 麻醉劑
  • 抗過敏
  • 其他

9. 全球眼科藥品市場依交付類型分類

  • 介紹
  • 局部的
  • 眼
    • 玻璃體內
    • 結膜下
  • 系統性
    • 口服
    • 靜脈

第 10 章全球眼科藥品市場（依通路）

  • 介紹
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 11 章全球眼科藥物市場（按地區）

  • 介紹
  • 北美洲
    • 按指示
    • 依產品類型
    • 按藥物形式
    • 按藥品類別
    • 透過交付
    • 按分銷管道
    • 按國家
      • 美國
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按指示
    • 依產品類型
    • 按藥物形式
    • 按藥品類別
    • 透過交付
    • 按分銷管道
    • 按國家
      • 巴西
      • 阿根廷
      • 其他
  • 歐洲
    • 按指示
    • 依產品類型
    • 按藥物形式
    • 按藥品類別
    • 透過交付
    • 按分銷管道
    • 按國家
      • 英國
      • 德國
      • 法國
      • 西班牙
      • 其他
  • 中東和非洲
    • 按指示
    • 依產品類型
    • 按藥物形式
    • 按藥品類別
    • 透過交付
    • 按分銷管道
    • 按國家
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 其他
  • 亞太地區
    • 按指示
    • 依產品類型
    • 按藥物形式
    • 按藥品類別
    • 透過交付
    • 按分銷管道
    • 按國家
      • 中國
      • 日本
      • 印度
      • 韓國
      • 台灣
      • 其他

第12章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第13章 公司簡介

  • Sun Pharmaceutical Industries, Inc.
  • AbbVie
  • Alcon Inc.（Ivantis）
  • Mundipharma International
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Sentiss Pharma Pvt. Ltd.
  • Santen Pharmaceutical Co., Ltd
  • Bausch & Lomb
  • Bayer AG
  • Aerie Pharmaceuticals, Inc

第14章 附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061613483

The Global Ophthalmic Drugs Market is expected to grow from USD 33.495 billion in 2025 to USD 47.031 billion in 2030, at a CAGR of 7.02%.

The Global Ophthalmic Drugs Market Study provides a comprehensive analysis of the evolving ophthalmic drugs industry, tailored for industry experts seeking actionable insights into market dynamics, technological advancements, and competitive strategies. This study examines key market segments, including indications, product types, drug forms, drug classes, delivery methods, distribution channels, and geographical regions, offering a detailed perspective on growth opportunities and challenges.

Study Overview

The Global Ophthalmic Drugs Market Study is structured to deliver a granular understanding of the market landscape. It covers critical aspects such as market drivers, restraints, opportunities, and technological trends shaping the industry. The study also includes a robust competitive analysis, highlighting strategic developments from key players to equip stakeholders with the insights needed to navigate this dynamic market. The analysis spans regions, including North America, South America, Europe, Middle East and Africa, and Asia Pacific, ensuring a global perspective.

Competitive Environment and Analysis

In the Global Ophthalmic Drugs Market Study, the competitive environment is a focal point, offering an in-depth look at major players and their strategic initiatives. Key developments from leading companies underscore the dynamic nature of the market:

  • Novartis AG: Novartis has strengthened its position through advancements in retinal disorder treatments, notably with its anti-VEGF therapy, Beovu (brolucizumab). The company has focused on expanding clinical trials to address unmet needs in wet age-related macular degeneration (AMD), positioning itself as a leader in the retinal problems segment. Its strategic partnerships with research institutions aim to accelerate innovation in intraocular delivery methods, enhancing treatment efficacy.
  • Alcon Inc. (Ivantis): Alcon has made significant strides in glaucoma management with its Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device. This development reflects Alcon's commitment to integrating drug-device combination therapies, addressing the growing demand for innovative delivery methods like subconjunctival administration. The company's acquisition of Ivantis has bolstered its portfolio, enhancing its competitive edge in the glaucoma indication segment.

These developments highlight how key players are leveraging innovation and strategic collaborations to capture market share and address evolving patient needs in the Global Ophthalmic Drugs Market Study.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Indication

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergies
  • Retinal Problems
  • Others

By Product type

  • OTC Drug
  • Prescription Drug

By Drug Form

  • Liquid
  • Semi-solid
  • Solid

By Drug Class

  • Anti-Inflammatory
  • Anesthetic
  • Anti-Allergy
  • Others

By Delivery Method

  • Topical (Eye Drops, Ointments)
  • Intraocular
  • Intravitreal
  • Subconjunctival
  • Systemic
  • Oral
  • Intravenous

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL OPHTHALMIC DRUGS MARKET BY INDICATION

  • 5.1. Introduction
  • 5.2. Dry Eye
  • 5.3. Glaucoma
  • 5.4. Infection/Inflammation/Allergies
  • 5.5. Retinal Problems
  • 5.6. Others

6. GLOBAL OPHTHALMIC DRUGS MARKET BY PRODUCT TYPE

  • 6.1. Introduction
  • 6.2. OTC Drug
  • 6.3. Prescription Drug

7. GLOBAL OPHTHALMIC DRUGS MARKET BY DRUG FORM

  • 7.1. Introduction
  • 7.2. Liquid
  • 7.3. Semi-solid
  • 7.4. Solid

8. GLOBAL OPHTHALMIC DRUGS MARKET BY DRUG CLASS

  • 8.1. Introduction
  • 8.2. Anti-Inflammatory
  • 8.3. Anesthetic
  • 8.4. Anti-Allergy
  • 8.5. Others

9. GLOBAL OPHTHALMIC DRUGS MARKET BY DELIVERY METHOD

  • 9.1. Introduction
  • 9.2. Topical
  • 9.3. Intraocular
    • 9.3.1. Intravitreal
    • 9.3.2. Subconjunctival
  • 9.4. Systemic
    • 9.4.1. Oral
    • 9.4.2. Intravenous

10. GLOBAL OPHTHALMIC DRUGS MARKET BY DISTRIBUTION CHANNEL

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. GLOBAL OPHTHALMIC DRUGS MARKET BY GEOGRAPHY

  • 11.1. Introduction
  • 11.2. North America
    • 11.2.1. By Indication
    • 11.2.2. By Product Type
    • 11.2.3. By Drug Form
    • 11.2.4. By Drug Class
    • 11.2.5. By Delivery Method
    • 11.2.6. By Distribution Channel
    • 11.2.7. By Country
      • 11.2.7.1. USA
      • 11.2.7.2. CanadaHybrid in
      • 11.2.7.3. Mexico
  • 11.3. South America
    • 11.3.1. By Indication
    • 11.3.2. By Product Type
    • 11.3.3. By Drug Form
    • 11.3.4. By Drug Class
    • 11.3.5. By Delivery Method
    • 11.3.6. By Distribution Channel
    • 11.3.7. By Country
      • 11.3.7.1. Brazil
      • 11.3.7.2. Argentina
      • 11.3.7.3. Others
  • 11.4. Europe
    • 11.4.1. By Indication
    • 11.4.2. By Product Type
    • 11.4.3. By Drug Form
    • 11.4.4. By Drug Class
    • 11.4.5. By Delivery Method
    • 11.4.6. By Distribution Channel
    • 11.4.7. By Country
      • 11.4.7.1. United Kingdom
      • 11.4.7.2. Germany
      • 11.4.7.3. France
      • 11.4.7.4. Spain
      • 11.4.7.5. Others
  • 11.5. Middle East and Africa
    • 11.5.1. By Indication
    • 11.5.2. By Product Type
    • 11.5.3. By Drug Form
    • 11.5.4. By Drug Class
    • 11.5.5. By Delivery Method
    • 11.5.6. By Distribution Channel
    • 11.5.7. By Country
      • 11.5.7.1. Saudi Arabia
      • 11.5.7.2. UAE
      • 11.5.7.3. Others
  • 11.6. Asia Pacific
    • 11.6.1. By Indication
    • 11.6.2. By Product Type
    • 11.6.3. By Drug Form
    • 11.6.4. By Drug Class
    • 11.6.5. By Delivery Method
    • 11.6.6. By Distribution Channel
    • 11.6.7. By Country
      • 11.6.7.1. China
      • 11.6.7.2. Japan
      • 11.6.7.3. India
      • 11.6.7.4. South Korea
      • 11.6.7.5. Taiwan
      • 11.6.7.6. Others

12. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 12.1. Major Players and Strategy Analysis
  • 12.2. Market Share Analysis
  • 12.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 12.4. Competitive Dashboard

13. COMPANY PROFILES

  • 13.1. Sun Pharmaceutical Industries, Inc.
  • 13.2. AbbVie
  • 13.3. Alcon Inc. (Ivantis)
  • 13.4. Mundipharma International
  • 13.5. F. Hoffmann-La Roche Ltd
  • 13.6. Novartis AG
  • 13.7. Sentiss Pharma Pvt. Ltd.
  • 13.8. Santen Pharmaceutical Co., Ltd
  • 13.9. Bausch & Lomb
  • 13.10. Bayer AG
  • 13.11. Aerie Pharmaceuticals, Inc

14. APPENDIX

  • 14.1. Currency
  • 14.2. Assumptions
  • 14.3. Base and Forecast Years Timeline
  • 14.4. Key benefits for the stakeholders
  • 14.5. Research Methodology
  • 14.6. Abbreviations